Sep 3, 2026 06:03AM
Aug 6, 2026 11:34AM
Jun 11, 2026 09:02AM
Jun 9, 2026 09:01AM
Apr 28, 2026 02:42PM
Apr 6, 2026 09:20AM
Mar 24, 2026 09:03AM NeuroSense reschedules Health Canada meeting to include additional data
Mar 10, 2026 02:59AM
Feb 18, 2026 09:05AM
Feb 9, 2026 09:20AM
Oct 14, 2025 09:46AM
May 12, 2025 07:08AM
Apr 24, 2025 09:09AM
Apr 9, 2025 08:30AM Neurosense Therapeutics (NRSN) Announces Transformative Phase 2b MicroRNA Data
Apr 8, 2025 11:21AM
Jan 6, 2025 09:02AM
Dec 16, 2024 08:13AM
Dec 11, 2024 09:25AM
Dec 2, 2024 08:32AM
Nov 19, 2024 04:18PM
Oct 28, 2024 08:30AM Neurosense Therapeutics (NRSN) Secures Key FDA Meeting to Advance its Phase 3 ALS Trial and NDA Submission
Oct 15, 2024 09:16AM
Oct 9, 2024 09:02AM
Sep 24, 2024 09:05AM
Sep 24, 2024 09:00AM
Aug 30, 2024 04:30PM
Aug 7, 2024 02:00PM
Aug 1, 2024 09:15AM Neurosense Therapeutics (NRSN) Reports Positive Biomarker Data from ALS Phase 2b Clinical Trial
Jul 9, 2024 09:27AM
Jul 1, 2024 08:07AM
Jun 21, 2024 04:30PM

448,576 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All